ArticleCancer gene therapy2019
Prognostic role of DOK family adapters in acute myeloid leukemia.
Article in Cancer gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- From genes to diagnosis: The impact of UNC5B and DOK5 in intracranial aneurysm detection and pathogenesis.PloS one · 2026Article
- Identification of exosome-related gene signature as a promising diagnostic and therapeutic tool for breast cancer.Heliyon · 2024Article
- Dok5 regulates proliferation and differentiation of osteoblast via canonical Wnt/β-catenin signaling.Journal of musculoskeletal & neuronal interactions · 2022Article
- Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors.Journal of advanced research · 2022Article
- Prognostic role of Wnt and Fzd gene families in acute myeloid leukaemia.Journal of cellular and molecular medicine · 2021Article
- DOK7 Inhibits Cell Proliferation, Migration, and Invasion of Breast Cancer via the PI3K/PTEN/AKT Pathway.Journal of oncology · 2021Article
- A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer.Cancers · 2020Article
- Prognostic role of SCAMP family in acute myeloid leukemia.The pharmacogenomics journal · 2020Article
- A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer.Cancers · 2020Article
- Prognostic value of the FUT family in acute myeloid leukemia.Cancer gene therapy · 2020Observational
- High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia.Cancer gene therapy · 2020Article
- Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.Journal of cellular and molecular medicine · 2020Article
- Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia.Frontiers in oncology · 2020Article
- Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia.Frontiers in oncology · 2020Article
- DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.Cancer medicine · 2019Article
- Next-Generation Sequencing Profiles of the Methylome and Transcriptome in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis.Journal of clinical medicine · 2019Article
- Prognostic value of the PDLIM family in acute myeloid leukemia.American journal of translational research · 2019Article
- HighCancer biology & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disease. Gene mutational and expressional profile can aid the identification of different prognostic subgroups. Downstream of tyrosine kinase (DOK) proteins are a multigenic family of adaptors; some of them are key negative regulators of immune cell signaling. However, the expression and clinical implication of DOK family in AML has rarely been investigated. A total of 155 AML patients with DOK family (DOK1-7) expression data from The Cancer Genome Atlas database were enrolled in the study. In patients who only received chemotherapy, those with high expressions of DOK4 or DOK5 had significantly shorter EFS and OS than patients with low expressions (all P < 0.001), whereas high DOK7 expressers had longer EFS and OS than the low expressers (all P < 0.05). In patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, all DOK members had no impact on EFS and OS. Multivariate analysis confirmed that high DOK5 expression was an independent risk factor for EFS and OS in untransplanted patients (all P < 0.05). Our study suggests that in AML, high expressions of DOK4 and DOK5 are adverse prognostic factors, high DOK7 expression is a good prognostic factor, but their effects can be overcome by allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.